INS and cancer: Dysfunctional WAT, present under obese conditions, leads to systemic changes that can impact cancer progression by inducing modifications in the circulating levels of WAT‐derived factors and insulin signaling, altering systemic lipid metabolism and triggering an inflammatory state (Fig. 4) [83, 84].